Goldman Sachs initiates Versigent coverage with Buy rating
Goldman Sachs analyst Mark Delaney initiated coverage on Versigent with a Buy rating and a $48 price target. This follows RBC Capital maintaining a Sector Perform rating with a $41 target, reflecting differing analyst views on the stock's potential.
*this image is generated using AI for illustrative purposes only.
Goldman Sachs analyst Mark Delaney has initiated coverage on Versigent (NYSE: VGNT) with a Buy rating and a price target of $48. This new endorsement contrasts with a recent outlook from RBC Capital, which maintained a Sector Perform rating while adjusting its own valuation expectations.
Rating and Price Target Details
The initiation by Goldman Sachs establishes a bullish stance on the stock, setting a price target that implies significant upside from current levels. This follows a separate assessment by RBC Capital analyst Tom Narayan, who maintained a neutral Sector Perform rating while raising the price target to $41, up from a previous $34.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| Goldman Sachs | Mark Delaney | Buy | $48 |
| RBC Capital | Tom Narayan | Sector Perform | $41 |
The divergence in ratings highlights differing views on Versigent's near-term trajectory and valuation potential within the sector.
What specific factors drove Goldman Sachs to adopt a more bullish stance compared to RBC's neutral outlook?
How might the market react to the diverging ratings from Goldman Sachs and RBC Capital in the coming weeks?
Could other major firms adjust their ratings on Versigent following Goldman's initiation and RBC's updated price target?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
